Bleakley Financial Group LLC Buys Shares of 12,551 IQVIA Holdings Inc. $IQV

Bleakley Financial Group LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, Holdings Channel reports. The fund purchased 12,551 shares of the medical research company’s stock, valued at approximately $2,384,000.

A number of other hedge funds also recently made changes to their positions in IQV. Premier Fund Managers Ltd raised its position in IQVIA by 24.2% during the third quarter. Premier Fund Managers Ltd now owns 311,823 shares of the medical research company’s stock valued at $56,402,000 after purchasing an additional 60,758 shares in the last quarter. EDENTREE ASSET MANAGEMENT Ltd bought a new position in shares of IQVIA during the 3rd quarter valued at about $7,368,000. Citigroup Inc. raised its holdings in shares of IQVIA by 108.2% during the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after buying an additional 475,557 shares in the last quarter. Sava Infond d.o.o. lifted its position in IQVIA by 11.3% in the 3rd quarter. Sava Infond d.o.o. now owns 15,910 shares of the medical research company’s stock worth $3,022,000 after buying an additional 1,620 shares during the last quarter. Finally, Raiffeisen Bank International AG boosted its stake in IQVIA by 4.4% in the third quarter. Raiffeisen Bank International AG now owns 7,010 shares of the medical research company’s stock worth $1,267,000 after buying an additional 296 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

IQV opened at $162.08 on Tuesday. The stock’s 50 day moving average price is $216.37 and its 200-day moving average price is $208.54. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The stock has a market capitalization of $27.50 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 1.60 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter in the previous year, the business posted $3.12 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on IQV shares. TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Jefferies Financial Group decreased their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Citigroup cut their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Finally, UBS Group dropped their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.